Gastrin/Cholecystokinin Type B Receptor Market Growth, Trends and Forecast
- Submitted by: Marketreport
- Views: 73
- Category: Other
- Date Submitted: 08/02/2016 02:35 AM
- Pages: 5
- Report this Essay
Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report GastrinCholecystokinin Type B Receptor Pipeline Review, H1 2016, outlays comprehensive information on the Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) Cholecystokinin B receptor also known as CCKBR is a G protein-coupled receptor for gastrin and cholecystokinin. The CKK-B receptors occur throughout the central nervous system where they modulate anxiety, analgesia, arousal, and neuroleptic activity. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Furthermore, this report also reviews key players involved in Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Gastrin/Cholecystokinin Type B Receptor...
Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) Cholecystokinin B receptor also known as CCKBR is a G protein-coupled receptor for gastrin and cholecystokinin. The CKK-B receptors occur throughout the central nervous system where they modulate anxiety, analgesia, arousal, and neuroleptic activity. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Furthermore, this report also reviews key players involved in Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Gastrin/Cholecystokinin Type B Receptor...